Previously, a PPAR-γ stimulating drug used in type 2 diabetes mellitus treatment (pioglitazone) was shown to inhibit ACKR3 expression in differentiated macrophages which resulted in suppressed chemotaxis [22]. Here, PPARG is linked to diabetes mellitus.